Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients with Hypertension-Reference-Cited by-同舟云学术

Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients with Hypertension

Published:2012-12 Issue:6 Volume:14 Page:401-409
ISSN:1174-5878
Container-title:Pediatric Drugs
language:en
Short-container-title:Pediatr Drugs

Author:

Wells Thomas G.,Blowey Douglas L.,Sullivan Janice E.,Blumer Jeffrey,Sherbotie Joseph R.,Song SaeHeum,Rohatagi Shashank,Heyrman Reinilde,Salazar Daniel E.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pediatrics, Perinatology and Child Health

Link

http://link.springer.com/content/pdf/10.1007/BF03262420.pdf

Reference27 articles.

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206–52

2. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008 Jan 1; 148 (1): 16–29

3. Franklin SS, Wachtell K, Papademetriou V, et al. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. Hypertension 2005 Sep; 46 (3): 492–9

4. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004 Aug; 114 (2 Suppl. 4th Report): 555–76

5. Flynn JT, Mitsnefes M, Pierce C, et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 2008 Oct; 52 (4): 631–7